NCT01459042

Brief Summary

Recent studies indicate that primary aldosteronism (PA) is a much more common cause of hypertension than had been demonstrated historically. In patients with resistant hypertension, the prevalence of PA from different clinics worldwide is about 10-20%. As has been no such data in China, the investigators are conducting a PA study in different province of China to evaluate the prevalence of PA in patients with resistant hypertension.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,000

participants targeted

Target at P75+ for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2010

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2011

Completed
20 days until next milestone

First Submitted

Initial submission to the registry

October 21, 2011

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 25, 2011

Completed
Last Updated

October 25, 2011

Status Verified

October 1, 2011

Enrollment Period

1.7 years

First QC Date

October 21, 2011

Last Update Submit

October 24, 2011

Conditions

Hypertension, Resistant to Conventional Therapy

Study Arms (2)

primary aldosteronism

essential hypertension

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with resistant hypertension from different provinces of China

You may qualify if:

  • patients with resistant hypertension
  • age 18-65 years

You may not qualify if:

  • known cause of hypertension
  • heart failure
  • renal dysfunction
  • Stroke, transient ischaemic attack or myocardial infarction in the past 6 months
  • cirrhosis
  • pregnancy
  • undertreatment of glucocorticoid

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Dep.endocrinology of Shanghai Ruijin Hospital, Shanghai Jiaotong university school of medcine

Shanghai, Shanghai Municipality, 200025, China

Location

Biospecimen

Retention: SAMPLES WITH DNA

blood samples,including serum, plasma and whole blood.

MeSH Terms

Conditions

Hypertension Resistant to Conventional Therapy

Study Officials

  • Weiqing Wang, MD, PhD

    Endocrinology Department of Ruijin Hospital affiliated Shanghai Jiao Tong University School of Medicine

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
ECOLOGIC OR COMMUNITY
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Endocrinology Department of Ruijin Hospital affiliated Shanghai Jiao Tong University School of Medicine

Study Record Dates

First Submitted

October 21, 2011

First Posted

October 25, 2011

Study Start

January 1, 2010

Primary Completion

October 1, 2011

Last Updated

October 25, 2011

Record last verified: 2011-10

Locations

CN(1)